KR20250065441A - 혈액 장애를 치료하기 위한 화합물 및 조성물 - Google Patents

혈액 장애를 치료하기 위한 화합물 및 조성물 Download PDF

Info

Publication number
KR20250065441A
KR20250065441A KR1020257014711A KR20257014711A KR20250065441A KR 20250065441 A KR20250065441 A KR 20250065441A KR 1020257014711 A KR1020257014711 A KR 1020257014711A KR 20257014711 A KR20257014711 A KR 20257014711A KR 20250065441 A KR20250065441 A KR 20250065441A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
optionally substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257014711A
Other languages
English (en)
Korean (ko)
Inventor
벤카테숴 라오 구마디
수산타 사마즈다르
카비타 넬로르
기리쉬 다기나카테
웨슬리 로이 발라수브라마니안
Original Assignee
오리진 온콜로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리진 온콜로지 리미티드 filed Critical 오리진 온콜로지 리미티드
Publication of KR20250065441A publication Critical patent/KR20250065441A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257014711A 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물 Pending KR20250065441A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201741011785 2017-03-31
IN201741011785 2017-03-31
KR1020247003678A KR20240019391A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
PCT/IB2018/052232 WO2018178947A2 (en) 2017-03-31 2018-03-30 Compounds and compositions for treating hematological disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003678A Division KR20240019391A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물

Publications (1)

Publication Number Publication Date
KR20250065441A true KR20250065441A (ko) 2025-05-12

Family

ID=63677680

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247003678A Ceased KR20240019391A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
KR1020197032104A Active KR102633530B1 (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
KR1020257014711A Pending KR20250065441A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020247003678A Ceased KR20240019391A (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물
KR1020197032104A Active KR102633530B1 (ko) 2017-03-31 2018-03-30 혈액 장애를 치료하기 위한 화합물 및 조성물

Country Status (25)

Country Link
US (2) US11419875B2 (enExample)
EP (2) EP4252853A3 (enExample)
JP (2) JP7333136B2 (enExample)
KR (3) KR20240019391A (enExample)
CN (2) CN120267671A (enExample)
AU (2) AU2018242623B2 (enExample)
BR (1) BR112019018991A2 (enExample)
CA (1) CA3056893A1 (enExample)
DK (1) DK3600270T3 (enExample)
EA (1) EA201992322A3 (enExample)
ES (1) ES2950764T3 (enExample)
FI (1) FI3600270T3 (enExample)
HR (1) HRP20230657T8 (enExample)
HU (1) HUE062648T2 (enExample)
IL (4) IL269536B (enExample)
LT (1) LT3600270T (enExample)
MX (2) MX389825B (enExample)
PH (1) PH12019502138A1 (enExample)
PL (1) PL3600270T3 (enExample)
PT (1) PT3600270T (enExample)
RS (1) RS64411B1 (enExample)
SG (1) SG11201908171TA (enExample)
SI (1) SI3600270T1 (enExample)
SM (1) SMT202300236T1 (enExample)
WO (1) WO2018178947A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3805233T3 (pl) 2014-01-13 2024-06-10 Aurigene Oncology Limited ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
EP3998264B1 (en) * 2019-07-10 2025-08-20 Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. Oxazole compound as multi-targeted inhibitor of irak4 and btk
WO2021047677A1 (zh) * 2019-09-12 2021-03-18 中国科学院上海药物研究所 一类irak4激酶抑制剂及其制备和应用
DK4097099T3 (da) 2020-02-07 2024-07-15 Gasherbrum Bio Inc Heterocyckliske GLP1-agonister
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
CN116419752A (zh) * 2020-08-03 2023-07-11 柯瑞斯公司 用于治疗疾病和病症的组合物和方法
CA3199157A1 (en) * 2020-11-18 2022-05-27 Reinhard Von Roemeling Methods of treating diseases and disorders
EP4269409A4 (en) * 2020-12-25 2024-12-11 Medshine Discovery Inc. AMIDE-OXAZOLE COMPOUND
CN114773331A (zh) * 2021-01-22 2022-07-22 武汉人福创新药物研发中心有限公司 苯并咪唑化合物及其用途
CN117120054A (zh) * 2021-04-08 2023-11-24 柯里斯公司 治疗癌症的组合疗法
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
WO2023088435A1 (zh) * 2021-11-19 2023-05-25 成都奥睿药业有限公司 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用
TWI890016B (zh) * 2021-12-23 2025-07-11 大陸商杭州多域生物技術有限公司 一種五員并六員化合物、製備方法、藥物組成物和應用
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
WO2015104688A1 (en) 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2015193846A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
WO2017009806A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
DE59010701D1 (de) 1990-05-18 1997-05-22 Hoechst Ag Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DK1348427T3 (da) 1997-07-29 2008-06-30 Alcon Lab Inc Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
WO2004098518A2 (en) 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Pyrazole-amide compounds useful as kinase inhibitors
EP2281823A3 (en) 2003-05-20 2011-09-07 Ajinomoto Co., Inc. Anti-inflammatory and analgesic piperidine derivatives
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050197364A1 (en) 2003-10-07 2005-09-08 Kelly Michael G. Amide compounds as ion channel ligands and uses thereof
MXPA06012104A (es) 2004-04-22 2007-01-25 Bayer Cropscience Lp Metodo y composicion para controlar malas hierbas.
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2006053227A2 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
BRPI0517425A (pt) 2004-12-17 2008-10-07 Lilly Co Eli composto ou um sal, solvato, enanciÈmero, diastereÈmero ou mistura de diastereÈmeros do mesmo, composição farmacêutica, uso de composto
DE602005017423D1 (de) 2004-12-17 2009-12-10 Lilly Co Eli Thiazolopyridinon-derivate als mch-rezeptorantagonisten
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
CA2641744C (en) 2006-02-10 2012-09-25 Transtech Pharma, Inc. Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
MX2008012482A (es) 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
US20080293785A1 (en) 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
KR20090049076A (ko) 2006-09-07 2009-05-15 바이오겐 아이덱 엠에이 인코포레이티드 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US20080153810A1 (en) 2006-11-15 2008-06-26 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
AU2007333194A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. LXR and FXR modulators
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CN101772500A (zh) * 2007-06-14 2010-07-07 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009012312A1 (en) 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
WO2009019167A1 (en) 2007-08-08 2009-02-12 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis
AU2009215191A1 (en) 2008-02-13 2009-08-20 Gilead Connecticut, Inc. 6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
EP2311842A3 (en) * 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
EP2367598B1 (en) 2008-11-19 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of diacylglycerol acyltransferase
US8283360B2 (en) 2008-12-19 2012-10-09 Merck Sharp & Dohme Corp. Bicyclic heterocyclic derivatives and methods of use thereof
CA2745866A1 (en) 2008-12-23 2010-07-01 F.Hoffmann-La Roche Ag Dihydropyridone ureas as p2x7 modulators
CN102480966B (zh) * 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
KR20120059558A (ko) * 2009-08-19 2012-06-08 암비트 바이오사이언시즈 코포레이션 바이아릴 화합물 및 이의 사용 방법
PT2488486T (pt) 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
WO2011137219A1 (en) 2010-04-30 2011-11-03 Schering Corporation Inhibitors of phosphoinositide dependent kinase 1 (pdk1)
SI2585064T1 (sl) 2010-06-24 2017-08-31 Chemocentryx, Inc. Antagonisti C5AR
MX358682B (es) 2010-07-13 2018-08-31 Hoffmann La Roche Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
KR20180099933A (ko) 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
HRP20161127T1 (hr) 2010-12-20 2016-11-18 Merck Serono S.A. Derivati indazolil triazola kao inhibitori irak
CN106974913A (zh) 2011-04-12 2017-07-25 美国卫生和人力服务部 用于治疗或预防疟疾的疟原虫表面阴离子通道抑制剂
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
RS54936B1 (sr) * 2011-10-14 2016-11-30 Ambit Biosciences Corp Heterociklična jedinjenja i njihova upotreba kao modulatora receptora tirozin kinaza tipa iii
CN104394869A (zh) 2011-10-20 2015-03-04 葛兰素史密斯克莱有限责任公司 用作沉默调节蛋白调节剂的取代的双环氮杂杂环化合物和类似物
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
EP2914592B1 (en) 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
US9168257B2 (en) 2013-05-22 2015-10-27 Children's Hospital Medical Center Combination therapy for MDS
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
MX2016010056A (es) 2014-02-06 2016-11-15 Abbvie Inc 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CU20180006A7 (es) 2015-07-15 2018-06-05 Aurigene Discovery Tech Ltd Compuestos de indazaol y azaindazol como inhibidores de irak-4
CA2993661A1 (en) 2015-08-04 2017-02-09 Rigel Pharmaceuticals, Inc. Benzazole compounds and methods for making and using the compounds
WO2018081738A1 (en) 2016-10-28 2018-05-03 Children's Hospital Medical Center Treatment of diseases associated with activated irak
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
JP7241747B2 (ja) 2017-10-31 2023-03-17 キュリス，インコーポレイテッド 血液学的障害を治療するための化合物および組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104662A1 (en) 2014-01-10 2015-07-16 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
WO2015104688A1 (en) 2014-01-13 2015-07-16 Aurigene Discovery Technologies Limited Bicyclic heterocyclyl derivatives as irak4 inhibitors
WO2015193846A1 (en) 2014-06-20 2015-12-23 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
WO2017009806A1 (en) 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Substituted aza compounds as irak-4 inhibitors

Also Published As

Publication number Publication date
MX2019011158A (es) 2019-10-17
US11419875B2 (en) 2022-08-23
AU2024203943A1 (en) 2024-07-04
PH12019502138A1 (en) 2020-06-29
EA201992322A3 (ru) 2020-09-30
EP4252853A2 (en) 2023-10-04
IL293783B1 (en) 2023-09-01
EA201992322A2 (ru) 2020-07-31
SI3600270T1 (sl) 2023-10-30
AU2018242623B2 (en) 2024-05-02
SG11201908171TA (en) 2019-10-30
US20220339161A1 (en) 2022-10-27
IL305150B1 (en) 2024-11-01
EP3600270A4 (en) 2020-08-26
JP7333136B2 (ja) 2023-08-24
IL269536B (en) 2022-07-01
IL305150A (en) 2023-10-01
CN120267671A (zh) 2025-07-08
HRP20230657T1 (hr) 2023-10-13
IL293783A (en) 2022-08-01
KR102633530B1 (ko) 2024-02-02
WO2018178947A2 (en) 2018-10-04
SMT202300236T1 (it) 2023-09-06
IL316364A (en) 2024-12-01
PT3600270T (pt) 2023-07-25
RS64411B1 (sr) 2023-09-29
EP4252853A3 (en) 2023-12-13
MX2022001343A (es) 2022-03-17
AU2018242623A1 (en) 2019-10-17
KR20240019391A (ko) 2024-02-14
ES2950764T3 (es) 2023-10-13
US20210290628A1 (en) 2021-09-23
EP3600270A2 (en) 2020-02-05
PL3600270T3 (pl) 2023-09-25
LT3600270T (lt) 2023-08-25
CN110691589A (zh) 2020-01-14
HRP20230657T8 (hr) 2023-11-10
IL305150B2 (en) 2025-03-01
IL269536A (en) 2019-11-28
IL293783B2 (en) 2024-01-01
NZ757707A (en) 2023-09-29
JP2023154005A (ja) 2023-10-18
MX389825B (es) 2025-03-20
JP2020512343A (ja) 2020-04-23
EP3600270B1 (en) 2023-06-14
DK3600270T3 (da) 2023-07-10
BR112019018991A2 (pt) 2020-04-14
KR20190130023A (ko) 2019-11-20
CA3056893A1 (en) 2018-10-04
FI3600270T3 (fi) 2023-07-20
HUE062648T2 (hu) 2023-11-28

Similar Documents

Publication Publication Date Title
KR102633530B1 (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
CN111225911B (zh) 用于治疗血液病的化合物和组合物
EP3416964B1 (en) 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
JP7156287B2 (ja) Ａｘｌ阻害剤を有効成分として含むがん治療剤
AU2023269214A1 (en) Treating diseases and disorders with irak4-modifying compounds
HK40013355A (en) Compounds and compositions for treating hematological disorders
NZ757707B2 (en) Compounds and compositions for treating hematological disorders
HK40031549B (zh) 用於治疗血液病的化合物和组合物
HK40031549A (en) Compounds and compositions for treating hematological disorders
JP2017507969A (ja) がん幹細胞標的化合物
JP2017507163A (ja) がん幹細胞の根絶または増殖阻害のための化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250502

Application number text: 1020247003678

Filing date: 20240131

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250530

Comment text: Request for Examination of Application